Literature DB >> 22409453

Minoxidil use in dermatology, side effects and recent patents.

Alfredo Rossi1, Carmen Cantisani, Luca Melis, Alessandra Iorio, Elisabetta Scali, Stefano Calvieri.   

Abstract

Minoxidil, a vasodilator medication known for its ability to slow or stop hair loss and promote hair regrowth, was first introduced, exclusively as an oral drug, to treat high blood pressure. It was however discovered to have the important side-effect of increasing growth or darkening of fine body hairs; this led to the development of a topical formulation as a 2% concentration solution for the treatment of female androgenic alopecia or 5% for treating male androgenic alopecia. Measurable changes disappear within months after discontinuation of treatment. The mechanism by which it promotes hair growth is not fully understood. Minoxidil is a potassium channel opener, causing hyperpolarization of cell membranes and it is also a vasodilator, it is speculated that, by widening blood vessels and opening potassium channels, it allows more oxygen, blood and nutrients to the follicle. This can also cause follicles in the telogen phase to shed, usually soon to be replaced by new, thicker hairs in a new anagen phase. It needs to be applied regularly, once or twice daily, for hair gained to be maintained, and side effects are common. The most common adverse reactions of the topical formulation are limited to irritant and allergic contact dermatitis on the scalp. There have been cases of allergic reactions to the nonactive ingredient propylene glycol, which is found in some topical solution especially if they are galenic. Increased hair loss which can occur during Minoxidil use, is due to the synchronization of the hair cycle that the treatment induces. In this review, we described its mechanism of action, use in dermatology and some patents related to alternative treatment of allergic reactions due to its use.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409453     DOI: 10.2174/187221312800166859

Source DB:  PubMed          Journal:  Recent Pat Inflamm Allergy Drug Discov        ISSN: 1872-213X


  49 in total

Review 1.  [Psoriasis and eczema on the scalp].

Authors:  D Wilsmann-Theis; T Bieber
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

Review 2.  Drug discovery for alopecia: gone today, hair tomorrow.

Authors:  Zenildo Santos; Pinar Avci; Michael R Hamblin
Journal:  Expert Opin Drug Discov       Date:  2015-02-09       Impact factor: 6.098

3.  Hirsutism in a female adolescent induced by long-acting injectable risperidone: a case report.

Authors:  Ankit Patel; Naaz Malek; Fasiha Haq; Lauren Turnbow; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2013

Review 4.  The shifting landscape of KATP channelopathies and the need for 'sharper' therapeutics.

Authors:  Sujay V Kharade; Colin Nichols; Jerod S Denton
Journal:  Future Med Chem       Date:  2016-05-10       Impact factor: 3.808

Review 5.  Androgenetic Alopecia: An Update of Treatment Options.

Authors:  Yanna Kelly; Aline Blanco; Antonella Tosti
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

6.  A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.

Authors:  Poonkiat Suchonwanit; Salinee Rojhirunsakool; Saranya Khunkhet
Journal:  Lasers Med Sci       Date:  2019-04-13       Impact factor: 3.161

Review 7.  KATP channels and cardiovascular disease: suddenly a syndrome.

Authors:  Colin G Nichols; Gautam K Singh; Dorothy K Grange
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

8.  Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.

Authors:  Gregory S Phillips; Morgan E Freret; Danielle Novetsky Friedman; Sabrina Trelles; Oluwaseun Kukoyi; Azael Freites-Martinez; Robin H Unger; Joseph J Disa; Leonard H Wexler; Christopher L Tinkle; James G Mechalakos; Stephen W Dusza; Kathryn Beal; Suzanne L Wolden; Mario E Lacouture
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

Review 9.  Adenosine Triphosphate-Sensitive Potassium Currents in Heart Disease and Cardioprotection.

Authors:  Colin G Nichols
Journal:  Card Electrophysiol Clin       Date:  2016-03-19

10.  An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia.

Authors:  Rachita Dhurat; Jill Chitallia; Theodor W May; Ammani M Jayaraaman; Jithendriya Madhukara; Subbu Anandan; Pradyumna Vaidya; Adolf Klenk
Journal:  Skin Pharmacol Physiol       Date:  2017-10-21       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.